This text is a result of machine translation.
Anjoy Foods Q3 Net Profit Totaled CNY 386 million, with an Impressive YoY Increase of 63.75%
China's Outbound Non-financial Direct Investment Increased 18.8% YoY
Survival Rules for Turbulent Times: A Compilation of the 20 Most Unmissable Core Insights from the 2026 Tsinghua PBCSF Forum
A dialogue between Zhu Min, former Deputy Governor of the People's Bank of China and former Vice Managing Director of the International Monetary Fund; Michael Spence, 2001 Nobel Prize winner in Economics and Philip H. Knight Professor Emeritus of Management at Stanford Graduate School of Business; and Masaaki Shirakawa, former Governor of the Bank of Japan, at the 2026 Tsinghua PBCSF Global Finance Forum.
May 18, 2026 02:22 PM
We-Linking Raised Over CNY 10 Mn in Angel Round
Intraoperative Neurophysiological Monitoring Equipment Developer NeuroFlag Closed An Angel Round
Innovative Drug Developer Rezu Bio Raised CNY 10 Mn in Series Pre-A
ZD Medtech Raised Over CNY 100 Mn in Series B
Smart Powered Bionic Prosthetic Star BionicM Nets Over CNY 10 Mn
Medical Technology Company MacroLux Nets Nearly CNY 100 Mn in Series A
Kanghong’s Conbercept Receives Marketing Authorization in Guyana
Kanghong Pharmaceutical (康弘药业) said its subsidiary Kanghong Bioscience had received a drug registration certificate from Guyana’s Food and Drug Department for conbercept ophthalmic injection, marketed under the brand name Lumitin (朗沐).
Yesterday 02:48 PM
Wantai BioPharm’s Nine-Valent HPV Vaccine Wins First Overseas Approval in Thailand
Wantai BioPharm (万泰生物) announced on Aug. 11 that the nine-valent HPV vaccine developed by its wholly owned subsidiary, Xiamen Innovax Biotech (万泰沧海), has received marketing authorization from Thailand’s Food and Drug Administration. The approval marks the vaccine’s first clearance outside China and an important step in Wantai BioPharm’s international expansion.
Aug 13, 2026 02:38 PM
CNC: net profit in the first quarter increased by 105.98% year-on-year
Baiji Shenzhou: 497 million yuan of excess placement funds will be included in the Securities Investor Protection Fund
Alphamab Licenses Cancer Drug to Pathos AI in Deal Worth More Than US$2.2 Billion
Alphamab Oncology (康宁杰瑞生物制药) has licensed the overseas rights to its experimental cancer drug JSKN016 to US-based Pathos AI in a deal potentially worth more than US$2.2 billion, marking another major overseas licensing agreement for China’s rapidly expanding innovative-drug sector.
Aug 06, 2026 05:41 PM
Mabwell Signs GCC Licensing Deal with Saudi Arabia’s SVAX for Aflibercept Biosimilar
Mabwell (Shanghai) Bioscience Co., Ltd.(迈威(上海)生物科技股份有限公司)has entered into a licensing agreement with Saudi Arabian biopharmaceutical company SVAX Inc. covering its aflibercept biosimilar, 9MW0813, in the Gulf Cooperation Council market.
Jul 31, 2026 03:00 PM
Film and television stocks rose in early trading and huanrui century trading limit
Zhongzi Technology: the lock of relevant shares of controlling shareholders, persons acting in concert and some directors and senior executives is extended for 6 months
Nenghui Technology: pre winning the EPC contract of Guangzhou Development Lechang changlai 60MW photovoltaic project
Nailing joined the industrial Internet Industry Alliance
Beyond Capital: Why Europe Needs Industrial Partners, Not Just Investors
Aug 04, 2026 11:21 AM
A Small Aircraft, a Bigger Bet: How China's Worthy Aero Plans to Scale Up
Jul 31, 2026 02:44 PM